US11684632 — Maribavir isomers, compositions, methods of making and methods of using
Method of Use · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2032-01-04 · 6y remaining
What this patent protects
This patent protects novel compositions and methods of using maribavir to enhance its effectiveness in medical therapy and counteract adverse effects of maribavir isomerization.
USPTO Abstract
The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
Drugs covered by this patent
- Livtencity (MARIBAVIR) · Takeda
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3650 |
— | Livtencity |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.